Discontinued — last reported Q4 '20

Operating Expenses

Deferred Rent Expense

Vertex Pharmaceuticals Deferred Rent Expense remained flat by 0.0% to -$127.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 46.4%, from -$87.20M to -$127.70M. Over 2 years (FY 2023 to FY 2025), Deferred Rent Expense shows relatively stable performance with a -2.4% CAGR.

Analysis

StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2013
Last reportedQ4 2020

How to read this metric

An increase suggests that cash payments are currently lower than the straight-line expense, while a decrease indicates the opposite.

Detailed definition

This metric captures the accounting adjustment required to recognize lease costs on a straight-line basis over the lease...

Peer comparison

Common in companies with significant real estate footprints; standard accounting practice under ASC 842.

Metric ID: is_tmusz_deferred_rent_expense

Historical Data

3 years
 FY'23FY'24FY'25
Value-$536.50M-$348.80M-$510.80M
YoY Change—+35.0%-46.4%
Range-$536.50M – -$348.80M
CAGR-2.4%
Avg YoY Growth-5.7%
Median YoY Growth-5.7%

Frequently Asked Questions

What is Vertex Pharmaceuticals's deferred rent expense?
Vertex Pharmaceuticals (VRTX) reported deferred rent expense of -$127.70M in Q4 2025.
How has Vertex Pharmaceuticals's deferred rent expense changed year-over-year?
Vertex Pharmaceuticals's deferred rent expense decreased by 46.4% year-over-year, from -$87.20M to -$127.70M.
What is the long-term trend for Vertex Pharmaceuticals's deferred rent expense?
Over 2 years (2023 to 2025), Vertex Pharmaceuticals's deferred rent expense has grown at a -2.4% compound annual growth rate (CAGR), from -$536.50M to -$510.80M.
What does deferred rent expense mean?
The difference between actual cash rent paid and the average rent expense recognized over the life of a lease.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.